1. In this case series, ruxolitinib was associated with improved inflammatory markers in patients with disabling pansclerotic morphea (DPM). 2. Ruxolitinib use was also associated with improved clinical symptoms in treated patients with DPM. Evidence Rating Level: 1 (Excellent) Study Rundown: DPM is a severe autoinflammatory disorder characterized by poor wound healing with rapidly progressive